sST2在慢性心力衰竭中独立于NT-proBNP和高敏肌钙蛋白T预测结局
该研究汇总慢性心衰患者个体数据,评估sST2独立预后价值。共纳入4268例患者,中位随访2.4年,全因死亡31%。在包含NT-proBNP和hs-TnT的模型中,sST2每翻倍,全因死亡、心血管死亡和心衰住院风险分别增加26%、25%和30%。sST2最佳切点为28 ng/ml,预测全因和心血管死亡及心衰住院的Kaplan-Meier分析log-rank分别为117.6、61.0和88.6(均p<0.001)。
要点
- sST2在慢性心衰中独立于NT-proBNP和hs-TnT预测全因死亡、心血管死亡和心衰住院。
- sST2每翻倍,全因死亡、心血管死亡和心衰住院风险分别增加26%、25%和30%。
- sST2最佳切点28 ng/ml,预测全因和心血管死亡及心衰住院的log-rank分别为117.6、61.0和88.6。
核心结论
- sST2对慢性心衰的全因死亡、心血管死亡和心衰住院具有强且独立的预测价值,值得考虑与NT-proBNP和hs-TnT一起纳入多标志物 panel。
研究设计与样本
- 汇总评估sST2用于慢性心衰风险预测的研究的个体患者数据,同时获取NT-proBNP和高敏肌钙蛋白T(hs-TnT)数据,共纳入4268例患者,中位年龄68岁,75%男性,65%缺血性心衰,87% LVEF<40%。
主要发现
- NT-proBNP、hs-TnT和sST2中位数分别为1360 ng/l(四分位区间513–3222 ng/l)、18 ng/l(9–33 ng/l)和27 ng/l(20–39 ng/l)。
- 中位随访2.4年,1319例(31%)发生全因死亡,其中心血管死亡932例(22%);4118例(96%)有数据患者中,1029例(24%)在2.2年内至少一次因心衰恶化住院。
- sST2预测全因死亡、心血管死亡和心衰住院的最佳切点为28 ng/ml,Kaplan-Meier分析log-rank分别为117.6、61.0和88.6(均p<0.001)。
- 在包含年龄、性别、体重指数、缺血性病因、LVEF、NYHA功能分级、肾小球滤过率、心衰药物治疗、NT-proBNP和hs-TnT的模型中,sST2每翻倍,全因死亡、心血管死亡和心衰住院风险分别增加26%、25%和30%。
- sST2在大多数亚组中保持独立预后价值。
关键数值与推荐
- sST2预测全因死亡、心血管死亡和心衰住院的最佳切点为28 ng/ml。
- 在调整年龄、性别、BMI、缺血性病因、LVEF、NYHA分级、eGFR、心衰药物治疗、NT-proBNP和hs-TnT后,sST2每翻倍,全因死亡风险增加26%,心血管死亡风险增加25%,心衰住院风险增加30%。
临床怎么用
- 在慢性心衰风险评估中,可考虑将sST2与NT-proBNP和hs-TnT联合使用以增强风险分层。
- sST2切点28 ng/ml可用于识别全因死亡、心血管死亡和心衰住院高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and fibrosis. OBJECTIVES: This study assessed the independent prognostic value of sST2 in chronic heart failure (HF). METHODS: Individual patient data from studies that assessed sST2 for risk prediction in chronic HF, together with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT), were retrieved. RESULTS: A total of 4,268 patients were evaluated (median age 68 years, 75% males, 65% with ischemic HF, 87% with left ventricular ejection fraction [LVEF] <40%). NT-proBNP, hs-TnT, and sST2 were 1,360 ng/l (interquartile interval: 513 to 3,222 ng/l), 18 ng/l (interquartile interval: 9 to 33 ng/l), and 27 ng/l (interquartile interval: 20 to 39 ng/l), respectively. During a 2.4-year median follow-up, 1,319 patients (31%) experienced all-cause death (n = 932 [22%] for cardiovascular causes). Among the 4,118 patients (96%) with available data, 1,029 (24%) were hospitalized at least once for worsening HF over 2.2 years. The best sST2 cutoff for the prediction of all-cause and cardiovascular death and HF hospitalization was 28 ng/ml, with good performance at Kaplan-Meier analysis (log-rank: 117.6, 61.0, and 88.6, respectively; all p < 0.001). In a model that included age, sex, body mass index, ischemic etiology, LVEF, New York Heart Association functional class, glomerular filtration rate, HF medical therapy, NT-proBNP, and hs-TnT, the risk of all-cause death, cardiovascular death, and HF hospitalization increased by 26%, 25%, and 30%, respectively, per each doubling of sST2. sST2 retained its independent prognostic value across most population subgroups. CONCLUSIONS: sST2 yielded strong, independent predictive value for all-cause and cardiovascular mortality, and HF hospitalization in chronic HF, and deserves consideration to be part of a multimarker panel together with NT-proBNP and hs-TnT.
引用
- Emdin M, Aimo A, Vergaro G, et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. J Am Coll Cardiol. 2018. PMID: 30384887. doi:10.1016/j.jacc.2018.08.2165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。